Full Press Release Details
Information as of and for the Six Months Ended June 30, 2018
In compliance with Nasdaq Stock
Market Rule 5250(c)(2), Bioblast Pharma Ltd. (the "Company") hereby furnishes its unaudited consolidated
statement of operations for the six months ended June 30, 2018 and its unaudited consolidated balance sheet as of
Consolidated Statement of Operations
(U.S. dollars in thousands, except share
and per share amounts)
| CONSOLIDATED STATEMENT OF OPERATIONS | ||||||||
| U.S. dollars | ||||||||
| Six Months Ended | ||||||||
| June 30 | June 30 | |||||||
| 2018 | 2017 | |||||||
| (Unaudited) | (Unaudited) | |||||||
| Research and development | $ | 159 | $ | 1,982 | ||||
| Pre-commercialization | - | 471 | ||||||
| General and administrative | 1,525 | 1,838 | ||||||
| Total operating expenses | 1,684 | 4,291 | ||||||
| Loss from operations | (1,684 | ) | (4,291 | ) | ||||
| Financial income, net | 7 | 29 | ||||||
| Loss before taxes on income | (1,677 | ) | (4,262 | ) | ||||
| Taxes on income | 17 | 43 | ||||||
| Net loss | $ | (1,694 | ) | $ | (4,305 | ) | ||
| Net loss attributable to Ordinary shareholders | $ | (1,694 | ) | $ | (4,305 | ) | ||
| Net loss per share attributable to Ordinary shareholders - basic and diluted | $ | (0.50 | ) | $ | (1.31 | ) | ||
| Weighted average number of Ordinary shares outstanding - basic and diluted | 3,356,523 | 3,284,489 |
Bioblast Pharma Ltd.
Consolidated Balance Sheet
(U.S. dollars in thousands, except share
| CONSOLIDATED BALANCE SHEET | ||||||||
| U.S. dollars | ||||||||
| June 30, 2018 | December 31, 2017 | |||||||
| (Unaudited) | (Audited) | |||||||
| ASSETS | ||||||||
| CURRENT ASSETS: | ||||||||
| Cash and cash equivalents | $ | 1,674 | $ | 3,526 | ||||
| Short-term bank deposits | - | - | ||||||
| Receivables and prepaid expenses | 30 | 96 | ||||||
| Property and equipment, net | - | - | ||||||
| Total current assets | 1,704 | 3,622 | ||||||
| LONG-TERM ASSETS: | - | - | ||||||
| TOTAL ASSETS | $ | 1,704 | $ | 3,622 | ||||
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||
| CURRENT LIABILITIES: | ||||||||
| Trade payables | $ | 13 | $ | 19 | ||||
| Other accounts payable | 131 | 441 | ||||||
| Total current liabilities | 144 | 460 | ||||||
| LONG-TERM LIABILITIES | - | - | ||||||
| SHAREHOLDERS' EQUITY: | ||||||||
| Ordinary shares of NIS 0.01 par value - 10,000,000 shares authorized at June 30, 2018 and December 31, 2017; Issued and outstanding shares 3,359,109 at June 30, 2018 and 3,342,393 at December 31, 2017 | 46 | 45 | ||||||
| Additional paid-in capital | 48,962 | 48,871 | ||||||
| Accumulated deficit | (47,448 | ) | (45,754 | ) | ||||
| Total stockholders' equity | 1,560 | 3,162 | ||||||
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $ | 1,704 | $ | 3,622 |